

May 12, 2025

<p>The Secretary, National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051</p> <p>NSE Code: ARTEMISMED</p>	<p>The Secretary, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001</p> <p>Scrip Code: 542919</p>
---	---

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on May 12, 2025

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we wish to inform you that the Board of Directors at its meeting held today, inter-alia, considered and approved the following:

1. Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2025.
2. Recommended the Final Dividend of Re. 0.45 per Equity Share of face value of Re. 1 each (i.e. 45%) for the financial year ended March 31, 2025, subject to the approval of the Shareholders at the ensuing Annual General Meeting (“AGM”) of the Company, which shall be paid/ dispatched on or before 30 days from the conclusion of AGM.
3. Appointment of Mr. Sunam Sarkar (DIN: 00058859) as an Additional Director in the category of Non-Executive, Non-Independent Director, effective from May 12, 2025, liable to retire by rotation, subject to the approval of the Shareholders at the ensuing AGM. Mr. Sunam Sarkar is not debarred from holding the office of the Director pursuant to any order of the SEBI or any other Authority.
4. Dr. Nirmal Kumar Ganguly (DIN: 02316154) has tendered his resignation as a Non-Executive, Non-Independent Director of the Company, and consequently from the membership of the Board Committees, effective from the close of business hours on May 12, 2025, due to personal reasons. The letter of resignation received from Dr. Nirmal Kumar Ganguly confirming that there are no other reasons for his resignation other than those mentioned in his letter is enclosed herewith.
5. Ms. Deepa Gopalan Wadhwa (DIN: 07862942) will cease to be a Director of the Company upon the completion of her term as an Independent Director on May 21, 2025.
6. Designated Mr. Pradeep Kumar Saha, Group Chief Information Officer, as a member of Senior Management of the Company, based on the recommendation of the Nomination and Remuneration Committee, effective from May 12, 2025.



7. Appointment of M/s. DMK Associates, Practicing Company Secretaries, as Secretarial Auditor of the Company to undertake the Secretarial Audit for a period of 5 (five) consecutive years, from FY 2025-26 to FY 2029-30, subject to the approval of the Shareholders of the Company at the ensuing AGM.

The details, as required under Regulation 30 and Schedule III of SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are provided in “**Annexure A**”.

Pursuant to Regulation 33 of SEBI Listing Regulations, please find enclosed herewith the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2025 along with the statements of Assets & Liabilities, Auditors' Report and declaration on Audit Reports with unmodified opinion.

In terms of Regulation 47 of SEBI Listing Regulations, the extract of the Audited Consolidated Financial Results for the quarter and year ended March 31, 2025, along with the Quick Response (QR) code and the details of the webpage where the complete financial results are accessible, shall be published in the newspapers.

The full format of the financial results shall be available on the website of the Stock Exchanges where equity shares of the Company are listed i.e. www.nseindia.com and www.bseindia.com and on Company's website www.artemishospitals.com.

The meeting of the Board of Directors commenced at 3:30 PM and concluded at 4:30 PM.

You are requested to take the same on your record.

Thanking you.

Yours faithfully,
For **Artemis Medicare Services Limited**

Poonam Makkar
Company Secretary & Compliance Officer

Encl: As above



Independent Auditor's Report on the Standalone Financial Results of Artemis Medicare Services Limited is pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).

To,
The Board of Directors of
Artemis Medicare Services Limited

Opinion

We have audited the accompanying Statement of Standalone Financial Results of **Artemis Medicare Services Limited** ('the Company') for the quarter and year ended March 31, 2025 (the "Standalone Financial Results"). The Standalone Financial Results have been submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulation").

In our opinion and to the best of our information and according to the explanation given to us, the aforesaid Standalone Financial Results:

- i. are presented in accordance with the requirement of Regulation 33 of the Listing Regulation; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the company for the quarter and year ended March 31, 2025.

Basis of Opinion

We conducted our audit of the Standalone Financial Results in accordance with the Standards on Auditing ("SA") specified under Section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the financial results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management and Board of Director's Responsibilities for the Standalone Financial Results

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Management and the Board of Directors and has been approved by them for issuance. The Standalone Financial Results for the year ended March 31, 2025, have been prepared from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2025, that give a true and fair view of the net profit and other comprehensive income of the Company and other financial information in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness the accounting



records, relevant to the preparation and presentation of the Standalone Financial Results, that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results as a whole are free from material misstatement, whether due to fraud or error and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Standalone Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.



- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Standalone Financial Results include the results for the quarter ended March 31, 2025 and the corresponding quarter ended in the previous year as reported in these Standalone financial results which are the balancing figure between the audited figures in respect of the full financial year and the published year to date figures up to the end of third quarter of the current and previous financial year respectively which were subject to limited review, as required under the Listing Regulations.

Our report on the Statement is not modified in respect of this matter.

For T R Chadha & Co LLP
Chartered Accountants
(Firm Registration No -006711N/ N500028)



Neena Goel
(Partner)
Membership No. 057986

Place of Signature:
Date: May 12, 2025
UDIN:25057986BBIKKV1546

ARTEMIS MEDICARE SERVICES LIMITED

CIN: L85110DL2004PLC126414

Registered office: Plot No.14, Sector 20, Dwarka, South West Delhi, Delhi- 110075

Ph.: +91-124-4511111; Email: investor@artemishospitals.com; Website: www.artemishospitals.com

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

(₹ in Lacs)

S No.	Particulars	Quarter ended			Year ended	
		31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24
		(Audited) (Refer Note 3)	(Unaudited)	(Audited) (Refer Note 3)	(Audited)	(Audited)
1.	Income					
	(a) Revenue from Operations	23,480.13	22,689.34	21,686.72	91,326.13	84,522.85
	(b) Other Income	1,223.30	880.34	186.95	3,291.50	728.61
	Total Income	24,703.43	23,569.68	21,873.67	94,617.63	85,251.46
2.	Expenses					
	(a) Operative Expenses	14,297.74	13,731.31	12,839.99	55,160.06	52,011.35
	(b) Purchases of Stock in Trade	-	-	-	-	-
	(c) Changes in inventories of Stock in Trade	-	-	-	0.54	-
	(d) Employee Benefits Expense	3,799.93	3,634.90	3,476.83	14,371.00	13,359.21
	(e) Finance Costs	752.82	765.42	807.60	3,048.26	2,959.23
	(f) Depreciation and Amortization Expense	1,124.82	1,094.38	1,045.87	4,301.80	3,803.19
	(g) Other Expenses	1,828.40	1,639.55	1,759.01	6,810.51	6,314.47
	Total Expenses	21,803.71	20,865.56	19,929.30	83,692.17	78,447.45
3.	Profit before exceptional items and tax (1-2)	2,899.72	2,704.12	1,944.37	10,925.46	6,804.01
4.	Exceptional Items	-	-	-	-	-
5.	Profit before tax (3+4)	2,899.72	2,704.12	1,944.37	10,925.46	6,804.01
6.	Tax Expense:					
	(a) Current Tax	356.03	591.39	391.09	2,111.26	1,224.14
	(b) Earlier Year Tax	20.96	-	41.39	20.96	41.39
	(c) Deferred Tax Charge / (Credit)	202.27	34.90	119.47	447.46	623.88
	Total Tax Expense	579.26	626.29	551.95	2,579.68	1,889.41
7.	Net Profit after tax (5-6)	2,320.46	2,077.83	1,392.42	8,345.78	4,914.60
8.	Other comprehensive income / (Loss)					
	Items that will not be reclassified to profit or loss					
	(a) Remeasurement gain/(loss) of defined employee benefit plans	50.01	(43.05)	(1.30)	(79.15)	(99.57)
	(b) Income Tax relating to items that will not be reclassified to profit or loss	(12.59)	10.84	0.33	19.92	25.06
	(c) Deferred Tax adjustment on revaluation that will not be reclassified to profit or loss	12.71	12.71	14.40	50.83	57.60
	Net Other comprehensive income / (Loss)	50.13	(19.50)	13.43	(8.40)	(16.91)
9.	Total comprehensive income (7+8)	2,370.59	2,058.33	1,405.85	8,337.38	4,897.69
10.	Paid up Equity Share Capital (Face value Re. 1/- each)	1,376.02	1,376.02	1,358.61	1,376.02	1,358.61
11.	Other Equity (Excluding Revaluation Reserves)	-	-	-	75,954.72	37,006.52
12.	Earning per Equity Share (Face value Re. 1/- each)					
	(a) Basic	1.48*	1.33*	1.02*	5.42	3.62
	(b) Diluted	1.47*	1.31*	1.00*	5.36	3.53

* Not annualised



Onkar Kaumar

Notes:-

1. The above standalone audited financial results for the quarter and year ended March 31, 2025 (financial results) have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on May 12, 2025. The statutory auditors, T R Chadha & Co LLP have expressed an unmodified opinion on the aforesaid financial results.

2. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended (Ind AS), as prescribed under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and the other recognised accounting practices and policies to the extent applicable and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

3. The results for the quarter ended March 31, 2025 and March 31, 2024, are the balancing figures between audited figures in respect of full financial year ended March 31, 2025 and March 31, 2024 respectively and published and unaudited respectively year to date figures up to the third quarter of the respective financial year then ended.

4. Segment Reporting:

The Company's operation predominantly comprises providing Healthcare services to patients. As per Ind AS 108 and our internal structure and information mechanisms, the Company has only one reportable business segment, i.e., "Healthcare Services".

Geographical information

Geographical information analyses the Company's revenue by the country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been based on the geographical location of the customers.

(₹ in Lacs)

Region	Revenue from Operations				
	Quarter ended			Year ended	
	31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24
India	16,233.11	16,202.61	15,956.67	65,893.47	61,890.61
Outside India	7,247.02	6,486.73	5,730.05	25,432.66	22,632.24
Total	23,480.13	22,689.34	21,686.72	91,326.13	84,522.85

Region	Carrying amount of Non-Current Assets				
	Quarter ended			Year ended	
	31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24
India	79,363.07	79,241.29	76,439.83	79,363.07	76,439.83
Outside India	-	-	-	-	-
Total	79,363.07	79,241.29	76,439.83	79,363.07	76,439.83

5. During the quarter and year ended March 31, 2025, the Company has issued Nil and 17,41,750 number of equity shares, respectively, each fully paid up at ₹1/- per share to its Managing Director pursuant to Artemis Medicare Management Stock Option Plan – 2021 (the Plan), which have been duly listed in the respective Stock Exchanges, ranking pari passu with the existing equity shares of the Company.

6. Pursuant to the approval of the Board in its meeting held on April 5, 2024, and subsequent approval of the members at Extra-ordinary General Meeting held on May 3, 2024, the Company has issued Compulsorily Convertible Debentures (carrying interest at the rate of 2.65% per annum, compounded quarterly on a cumulative basis) of a face value of Rs. 100,000 (Rupees One Lakh) each ("CCDs") to International Finance Corporation ("IFC"), a qualified institutional buyer, and who does not belong to the promoter/ promoter group of the Company, by way of a preferential issue on a private placement basis for an amount of Rs. 33,000 Lakhs. As per the terms of the Subscription Agreement and Policy Right Agreement ("IFC SAPR Agreements") CCDs shall be convertible into equity shares of the Company having a face value of Re. 1/- (Rupee One only) each ("Equity Shares"), in one or more tranches, within a period up to 18 (eighteen) months from the date of allotment of the CCDs, at a price of Rs. 174.03/- (Rupees One Hundred Seventy-Four and Three Paise only) per Equity Share, such that the total number of Equity Shares to be issued pursuant to the conversion of all CCDs shall not exceed 1,89,62,247 Equity Shares. The Equity Shares to be issued pursuant to the conversion of CCDs shall rank pari-passu with the existing Equity Shares of the Company in all respects, including as to dividend and voting powers. In accordance with Ind AS 109, the equity component of CCD's amounting to Rs 32,061.30 Lacs has been accounted for in other equity.

Further, as per applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has received necessary in-principle approval of BSE Ltd. and National Stock Exchange of India Limited on May 7, 2024 in relation to issuance of 1,89,62,247 Equity Shares upon conversion of such CCDs.

7. The Board of Directors have recommended a final dividend of Re. 0.45/- per Equity Share of face value of Re. 1 each (i.e. 45%) for FY25, subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM) of the Company, which shall be paid/ dispatched on or before 30 days from the conclusion of AGM.

8. The previous period's/year's figures have been regrouped/reclassified wherever necessary to correspond with the current period/year classification/disclosures.



For and on behalf of the Board of Directors of
Artemis Medicare Services Limited

Onkar Kanwar

Onkar Kanwar
Chairman
DIN: 00058921

Place : London
Date : May 12, 2025



Artemis Medicare Services Limited
Standalone Statement of Assets & Liabilities as at 31st March, 2025

(₹ in Lacs)

Particulars	Note	As At 31st March 2025 (Audited)	As At 31st March 2024 (Audited)
Assets			
Non-current assets			
Property, plant and equipment	2.1	63,989.74	59,069.64
Capital work-in-progress		3,872.40	3,344.73
Right-of-use assets	2.2	3,946.50	6,016.49
Goodwill		4,162.07	4,162.07
Other Intangible assets	2.3	812.42	675.26
Other Intangible assets under development		167.56	-
Financial assets			
i. Investments	3.1	1,501.50	1,501.50
ii. Loans	3.2	148.17	56.99
iii. Other financial assets	3.3	563.30	403.72
Non-current tax assets (Net)	4	1,906.90	2,637.83
Other non-current assets	5	505.48	533.81
Total non-current assets	A	81,576.04	78,402.04
Current assets			
Inventories	6	933.39	909.43
Financial assets			
i. Trade receivables	7	9,285.88	8,349.95
ii. Cash and cash equivalents	8	4,101.12	1,325.58
iii. Bank balances other than (ii) above	9	35,225.12	4,468.36
iv. Loans	3.2	163.68	200.57
v. Other financial assets	3.3	2,126.03	677.97
Other current assets	5	899.27	469.37
Total current assets	B	52,734.49	16,401.23
Total Assets	C = A + B	1,34,310.53	94,803.27
Equity and liabilities			
Equity			
Equity share capital	10	1,376.02	1,358.61
Other equity	11	82,803.77	43,804.75
Total equity	D	84,179.79	45,163.36
Non-current liabilities			
Financial liabilities			
i. Borrowings	12	20,412.35	21,648.77
ii. Lease Liabilities		3,964.04	5,854.61
Provisions	13	1,255.84	1,032.39
Deferred tax liabilities (Net)	14	3,750.01	3,677.48
Total non-current liabilities	E	29,382.24	32,213.25
Current liabilities			
Financial liabilities			
i. Borrowings	15	3,191.97	2,172.05
ii. Lease Liabilities		481.50	814.96
iii. Trade payables			
(A) Total Outstanding dues of Micro Enterprises and Small Enterprises	16	1,595.45	1,126.41
(B) Total Outstanding dues of Creditors other than Micro Enterprises and Small Enterprises	16	8,125.33	7,766.38
iv. Other financial liabilities	17	3,334.77	2,121.64
Other current liabilities	18	2,615.43	2,170.13
Provisions	13	1,404.05	1,255.09
Total current liabilities	F	20,748.50	17,426.66
Total liabilities	G = E + F	50,130.74	49,639.91
Total equity and liabilities	H = D + G	1,34,310.53	94,803.27



Onuse Kaumap

Artemis Medicare Services Limited
Standalone Statement of Cash Flow for the year ended 31st March, 2025

Particulars	(₹ in Lacs)	
	Year ended 31st March 2025 (Audited)	Year ended 31st March 2024 (Audited)
Cash flow from operating activities		
Profit before tax	10,925.46	6,804.01
Adjustments for:		
Depreciation and amortization expense	4,301.80	3,803.19
Interest Income	(2,652.61)	(409.28)
Finance Cost	2,722.50	2,621.49
Employee Cost towards Stock Based Payments	92.98	217.54
Unclaimed Credit balances / provisions no longer required written back	(44.72)	(115.83)
Allowance for Expected Credit Loss	174.29	151.29
Bad Debts Written Off	29.53	23.15
Unrealised foreign exchange gain (net)	10.66	3.26
Export Incentive (Deferred government grant)	-	(659.35)
Loss/ (Gain) on Lease Adjustment	(219.19)	-
Loss / (Gain) on Sale / Scrap of Property, Plant and Equipment (Net)	9.96	(21.43)
Operating cash flow before working capital changes	15,350.66	12,418.04
Adjustments for Changes in Working Capital		
- (Increase)/ Decrease in trade receivables	(1,150.41)	(46.84)
- (Increase)/ Decrease in inventories	(23.96)	365.44
- (Increase)/ Decrease in other financial assets (Current)	(358.29)	19.92
- (Increase)/ Decrease in other financial assets (Non - Current)	(97.27)	43.10
- (Increase)/ Decrease in other Current Assets	(429.91)	(37.29)
- (Increase)/ Decrease in Other Non Current Assets	28.33	(136.12)
- Increase/(Decrease) in trade payables	872.71	694.08
- Increase/(Decrease) in Provisions (Current)	148.96	130.02
- Increase/(Decrease) in Provisions (Non - Current)	144.30	50.73
- Increase / (Decrease) in Other current liabilities (Current)	445.29	(111.51)
- Increase / (Decrease) in Other financial liabilities (Current)	378.76	(1,195.29)
Cash generated from operations	15,309.17	12,194.28
Income tax refund / (paid)	(1,401.29)	(1,435.00)
Net cash generated from operating activities (A)	13,907.88	10,759.28
Cash flow from investing activity		
Purchase of Property, Plant & Equipment / CWIP	(9,298.95)	(7,180.56)
Proceeds from sale of Property, Plant & Equipment	14.29	32.42
Maturity / (investments) of / in fixed deposits having original maturity of more than 3 months *	(30,738.19)	(1,802.02)
Investment made in subsidiary	-	(331.50)
Loans and Advances given	(30.74)	(93.75)
Interest received	1,225.58	384.69
Net cash (used in) investing activities (B)	(38,828.01)	(8,990.72)
Cash flow from financing activity		
Proceeds from non current borrowings	2,278.39	4,532.53
Repayment of non current borrowings	(3,032.42)	(3,099.78)
Proceeds from issuance of Equity Share Capital (ESOP)	17.42	17.42
Proceeds from issuance of CCD	33,000.00	-
CCD Transaction Cost	(910.81)	-
Payment of lease liabilities - Principal amount	(440.94)	(388.24)
Payment of lease liabilities - Interest amount	(525.30)	(520.89)
Dividend paid	(597.55)	(611.37)
Interest paid	(2,093.11)	(2,539.26)
Net cash generated from financing activities (C)	27,695.68	(2,609.59)
Net increase in cash & cash equivalents A + B + C	2,775.55	(841.03)
Cash & cash equivalents as the beginning of the year	1,325.58	2,166.61
Cash & cash equivalents as the end of the year Total	4,101.13	1,325.58
Components of cash and cash equivalents		
Cash on hand	131.41	102.82
Balances with Banks:		
On current accounts	1,414.72	725.76
Fixed Deposit in banks having original maturity of 3 months or less	2,555.00	497.00
Total Cash and Cash Equivalents Total	4,101.13	1,325.58

(Note : * This includes investment in fixed deposits of funds received from issuance of CCD amounting to Rs 32205.91 Lacs)



Onkar Kaumar



Independent Auditor's Report on the Consolidated Financial Results of Artemis Medicare Services Limited pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors of
Artemis Medicare Services Limited

Opinion

We have audited the accompanying Statement of Consolidated Financial Results of **Artemis Medicare Services Limited** ('the Holding') and its subsidiary (the Holding and its subsidiary together referred to as 'the Group') for the quarter and for the year ended March 31, 2025 ("Consolidated Financial Results"). The Consolidated Financial Results have been submitted by the Holding Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of the other auditors on separate audited financial statements and other financial information of the subsidiary, the Consolidated Financial Results:

- i. includes the Standalone Financial Results of the following entities:
 - a. Holding Company: Artemis Medicare Services Limited
 - b. Subsidiary held directly: Artemis Cardiac Care Private Limited
- ii. is presented in accordance with the requirement of Regulation 33 of the Listing Regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- iii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group for the quarter and for the year ended March 31, 2025.

Basis of Opinion

We conducted our audit of the Statement in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their report referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the consolidated annual financial results.

Management's and Board of Directors' Responsibilities for the Consolidated Financial Results

This Statement, which includes the Consolidated Financial Results is the responsibility of the Holding Company's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2025, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results

for the quarter and year ended March 31, 2025 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Management and Board of Directors of the Companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent, design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated Financial Results, that give a true and fair view and is free from material misstatement, whether due to fraud or error which have been used for the purpose of preparation of the Consolidated Financial Results by the Management and the Directors of the Holding Company, as aforesaid.

In preparing the Consolidated Financial Results, the respective Management and the Board of Directors of the Companies included in the Group are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are also responsible for overseeing the financial reporting process of each Company.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results as a whole is free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.

Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.

- Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Results, including the disclosures, and whether the Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial results of the entities within the Group of which we are the independent auditors and whose financial information we have audited, to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of the financial information of such entities included in the Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Results.


We communicate with those charged with governance of the Parent Company and the entities included in the Consolidated Financial Results of which we are the auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters


- The Consolidated Financial Results include the results for the quarter ended March 31, 2025 and the corresponding quarter ended in the previous year as reported in these Consolidated financial results which are the balancing figure between the audited figures in respect of the full financial year and the published year to date figures up to the end of third quarter of the current and previous financial year respectively which were subject to limited review, as required under the Listing Regulations.
- We did not audit the financial results of one subsidiary i.e., Artemis Cardiac Care Private Limited included in the consolidated financial results, whose financial results reflect total assets of ₹ 3,115.73 lakhs as at March 31, 2025 and total revenues of ₹ 524.99 lakhs and ₹ 2,394.15 lakhs for the quarter and year ended March 31, 2025 respectively, total comprehensive income/(loss) of ₹ (29.94) lakhs and ₹ (129.88)



lakhs for the quarter and year ended March 31, 2025 respectively and net cash inflows/(outflow) of ₹ (77.59) lakhs for the year ended March 31, 2025, as considered in the Statement. These financial results have been audited, as applicable, by other auditors whose reports have been furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated under Auditor's Responsibilities section above.

Our Opinion is not modified in respect of these matters.

For T R Chadha & Co LLP
Chartered Accountants
(Firm Registration No -006711N/ N500028)



Neena Goel
(Partner)
Membership No. 057986

Place of Signature: Gurugram
Dated: May 12, 2025
UDIN: 25057986BBIKKX1258

ARTEMIS MEDICARE SERVICES LIMITED

CIN: L85110DL2004PLC126414

Registered office: Plot No.14, Sector 20, Dwarka, South West Delhi, Delhi- 110075

Ph.: +91-124-4511111; Email: investor@artemishospitals.com; Website: www.artemishospitals.com

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

(₹ in Lacs)

S No.	Particulars	Quarter ended			Year ended	
		31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24
		(Audited) (Refer Note 3)	(Unaudited)	(Audited) (Refer Note 3)	(Audited)	(Audited)
1.	Income					
	(a) Revenue from Operations	23,990.01	23,239.14	22,524.07	93,691.67	87,857.43
	(b) Other Income	1,234.50	879.75	189.80	3,298.59	735.39
	Total Income	25,224.51	24,118.89	22,713.87	96,990.26	88,592.82
2.	Expenses					
	(a) Operative Expenses	14,591.47	14,044.25	13,410.83	56,521.05	54,030.89
	(b) Purchases of Stock in Trade	-	-	-	-	-
	(c) Changes in inventories of Stock in Trade	-	-	-	0.54	-
	(d) Employee Benefits Expense	3,914.30	3,747.14	3,605.85	14,837.26	13,894.63
	(e) Finance Costs	783.22	800.18	857.46	3,194.48	3,128.66
	(f) Depreciation and Amortization Expense	1,174.28	1,145.04	1,103.83	4,516.49	4,031.65
	(g) Other Expenses	1,894.82	1,701.39	1,712.17	7,153.86	6,661.71
	Total Expenses	22,358.09	21,438.00	20,690.14	86,223.68	81,747.54
3.	Profit before exceptional items and tax (1-2)	2,866.42	2,680.89	2,023.73	10,766.58	6,845.28
4.	Exceptional Items	-	-	-	-	-
5.	Profit before tax (3+4)	2,866.42	2,680.89	2,023.73	10,766.58	6,845.28
6.	Tax Expense:					
	(a) Current Tax	356.03	591.39	391.09	2,111.26	1,224.14
	(b) Earlier Year Tax	20.96	-	41.39	20.96	41.39
	(c) Deferred Tax Charge / (Credit)	197.04	29.77	160.83	416.74	665.28
	Total Tax Expense	574.03	621.16	593.31	2,548.96	1,930.81
7.	Net Profit after tax (5-6)	2,292.39	2,059.73	1,430.42	8,217.62	4,914.47
8.	Other comprehensive income / (Loss)					
	Items that will not be reclassified to profit or loss					
	(a) Remeasurement gain/(loss) of defined employee benefit plans	50.11	(43.73)	(1.89)	(81.08)	(99.96)
	(b) Income Tax relating to items that will not be reclassified to profit or loss	(12.61)	11.01	0.48	20.41	25.16
	(c) Deferred Tax adjustment on revaluation that will not be reclassified to profit or loss	12.71	12.71	14.40	50.83	57.60
	Net Other comprehensive income / (Loss)	50.21	(20.01)	12.99	(9.84)	(17.20)
9.	Total comprehensive income (7+8)	2,342.60	2,039.72	1,443.41	8,207.78	4,897.27
10.	Profit / (Loss) attributable to :					
	Shareholders of the Company	2,302.92	2,066.79	1,417.93	8,262.58	4,914.06
	Non-Controlling Interest	(10.51)	(7.05)	12.48	(44.96)	0.41
11.	Total Comprehensive Income / (Loss) attributable to :					
	Shareholders of the Company	2,353.09	2,046.94	1,431.07	8,253.24	4,896.96
	Non-Controlling Interest	(10.49)	(7.22)	12.33	(45.46)	0.31
12.	Paid up Equity Share Capital (Face value Re. 1/- each)	1,376.02	1,376.02	1,358.61	1,376.02	1,358.61
13.	Other Equity (Excluding Revaluation Reserves)	-	-	-	75,542.52	36,678.45
14.	Earning per Equity Share (Face value Re. 1/- each)					
	(a) Basic	1.47*	1.32*	1.04*	5.37	3.62
	(b) Diluted	1.45*	1.31*	1.02*	5.31	3.53

* Not annualised



Onkar Kaumar

Notes:-

1. The above audited Consolidated financial results of Artemis Medicare Services Limited (the Company) and one Subsidiary Company (together referred as 'the Group') for the quarter and year ended March 31, 2025, have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on May 12, 2025. The statutory auditors have expressed an unmodified opinion on the aforesaid financial results.

2. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended (Ind AS), as prescribed under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and the other recognised accounting practices and policies to the extent applicable and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

3. The results for the quarter ended March 31, 2025 and March 31, 2024, are the balancing figures between audited figures in respect of full financial year ended March 31, 2025 and March 31, 2024 respectively and published and unaudited respectively year to date figures up to the third quarter of the respective financial year then ended.

4. Segment Reporting:

The Group's operation predominantly comprises providing Healthcare services to patients. As per Ind AS 108 and our internal structure and information mechanisms, the Group has only one reportable business segment, i.e., "Healthcare Services".

Geographical information

Geographical information analyses the Group's revenue by the Group's country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been based on the geographical location of the customers.

(₹ in Lacs)

Region	Revenue from Operations				
	Quarter ended			Year ended	
	31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24
India	16,742.99	16,752.41	16,794.02	68,259.01	65,225.19
Outside India	7,247.02	6,486.73	5,730.05	25,432.66	22,632.24
Total	23,990.01	23,239.14	22,524.07	93,691.67	87,857.43

Region	Carrying amount of Non-Current Assets				
	Quarter ended			Year ended	
	31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24
India	81,142.92	81,234.62	78,679.99	81,142.92	78,679.99
Outside India	-	-	-	-	-
Total	81,142.92	81,234.62	78,679.99	81,142.92	78,679.99

5. During the quarter and year ended March 31, 2025, the Parent Company has issued Nil and 17,41,750 number of equity shares, respectively, each fully paid up at ₹1/- per share to its Managing Director pursuant to Artemis Medicare Management Stock Option Plan – 2021 (the Plan), which have been duly listed in the respective Stock Exchanges, ranking pari passu with the existing equity shares of the parent Company.

6. Pursuant to the approval of the Board in its meeting held on April 5, 2024, and subsequent approval of the members at Extra-ordinary General Meeting held on May 3, 2024, the Parent Company has issued Compulsorily Convertible Debentures (carrying interest at the rate of 2.65% per annum, compounded quarterly on a cumulative basis) of a face value of Rs. 100,000 (Rupees One Lakh) each ("CCDs") to International Finance Corporation ("IFC"), a qualified institutional buyer, and who does not belong to the promoter/ promoter group of the Company, by way of a preferential issue on a private placement basis for an amount of Rs. 33,000 Lakhs. As per the terms of the Subscription Agreement and Policy Right Agreement ("IFC SAPR Agreements") CCDs shall be convertible into equity shares of the Company having a face value of Re. 1/- (Rupee One only) each ("Equity Shares"), in one or more tranches, within a period up to 18 (eighteen) months from the date of allotment of the CCDs, at a price of Rs. 174.03/- (Rupees One Hundred Seventy-Four and Three Paise only) per Equity Share, such that the total number of Equity Shares to be issued pursuant to the conversion of all CCDs shall not exceed 1,89,62,247 Equity Shares. The Equity Shares to be issued pursuant to the conversion of CCDs shall rank pari-passu with the existing Equity Shares of the Parent Company in all respects, including as to dividend and voting powers. In accordance with Ind AS 109, the equity component of CCD's amounting to Rs 32,061.30 Lacs has been accounted for in other equity.

Further, as per applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Parent Company has received necessary in-principle approval of BSE Ltd. and National Stock Exchange of India Limited on May 7, 2024 in relation to issuance of 1,89,62,247 Equity Shares upon conversion of such CCDs.

7. The Board of Directors have recommended a final dividend of Re. 0.45/- per Equity Share of face value of Re. 1 each (i.e. 45%) for FY25, subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM) of the Parent Company, which shall be paid/ dispatched on or before 30 days from the conclusion of AGM.

8. The previous period's/year's figures have been regrouped/reclassified wherever necessary to correspond with the current period/year classification/disclosures.

Place : London
Date : May 12, 2025



For and on behalf of the Board of Directors of
Artemis Medicare Services Limited

Onkar Kanwar

Onkar Kanwar
Chairman
DIN: 00058921



Artemis Medicare Services Limited
Consolidated Statement of Assets & Liabilities as at 31st March, 2025

(₹ in Lacs)

Particulars	Note	As At 31st March 2025 (Audited)	As At 31st March 2024 (Audited)
Assets			
Non-current assets			
Property, plant and equipment	2.1	65,523.61	61,049.62
Capital work-in-progress		3,872.40	3,344.73
Right-of-use assets	2.2	3,946.50	6,016.49
Goodwill		4,162.07	4,162.07
Other Intangible assets	2.3	837.64	698.62
Other Intangible assets under development		167.56	-
Financial assets			
i. Loans	3.2	148.17	57.55
ii. Other financial assets	3.3	563.30	403.72
Non-current tax assets (Net)	4	2,127.38	2,874.62
Other non-current assets	5	505.76	533.84
Total non-current assets	A	81,854.39	79,141.26
Current assets			
Inventories	6	997.73	1,008.27
Financial assets			
i. Trade receivables	7	10,132.40	9,482.33
ii. Cash and cash equivalents	8	4,158.85	1,460.88
iii. Bank balances other than (ii) above	9	35,394.83	4,673.36
iv. Loans	3.2	164.94	202.24
v. Other financial assets	3.3	2,127.67	701.33
Other current assets	5	909.89	481.60
Total current assets	B	53,886.31	18,010.01
Total Assets	C = A + B	1,35,740.70	97,151.27
Equity and liabilities			
Equity			
Equity share capital	10	1,376.02	1,358.61
Other equity	11	82,391.57	43,476.68
Equity attributable to shareholders of the Company		83,767.59	44,835.29
Non-controlling Interests		587.60	633.05
Total equity	D	84,355.19	45,468.34
Liabilities			
Non-current liabilities			
Financial liabilities			
i. Borrowings	12	20,947.94	22,771.77
ii. Lease Liabilities		3,964.04	5,854.61
Provisions	13	1,284.75	1,057.19
Deferred tax liabilities (Net)	14	3,575.78	3,534.46
Total non-current liabilities	E	29,772.51	33,218.03
Current liabilities			
Financial liabilities			
i. Borrowings	15	3,634.24	2,584.54
ii. Lease Liabilities		481.50	814.96
iii. Trade payables			
(A) Total Outstanding dues of Micro Enterprises and Small Enterprises	16	1,763.15	1,376.08
(B) Total Outstanding dues of Creditors other than Micro Enterprises and Small Enterprises	16	8,349.20	8,075.45
iv. Other financial liabilities	17	3,345.10	2,166.46
Other current liabilities	18	2,630.18	2,187.59
Provisions	13	1,409.63	1,259.82
Total current liabilities	F	21,613.00	18,464.90
Total liabilities	G = E + F	51,385.51	51,682.93
Total equity and liabilities	H = D + G	1,35,740.70	97,151.27



Onuse kaumar



Artemis Medicare Services Limited
Consolidated Statement of Cash Flow for the year ended 31st March, 2025

Particulars	(₹ in Lacs)	
	Year ended 31st March 2025 (Audited)	Year ended 31st March 2024 (Audited)
Cash flow from operating activities		
Profit before tax	10,766.58	6,845.28
Adjustments for:		
Depreciation and amortization expense	4,516.49	4,031.65
Interest Income	(2,662.45)	(425.29)
Finance Cost	2,846.31	2,776.06
Employee Cost towards Stock Based Payments	92.98	217.54
Unclaimed Credit balances / provisions no longer required written back	(44.72)	(115.83)
Allowance for Expected Credit Loss	275.22	189.89
Bad Debts Written Off	29.53	23.15
Unrealised foreign exchange gain (net)	10.66	3.26
Export Incentive (Deferred government grant)	-	(659.35)
Loss/ (Gain) on Lease Adjustment	(219.19)	-
Loss / (Gain) on Sale / Scrap of Property, Plant and Equipment (Net)	5.73	(21.43)
Operating cash flow before working capital changes	15,617.14	12,864.93
Adjustments for Changes in Working Capital		
- (Increase)/ Decrease in trade receivables	(965.48)	(371.01)
- (Increase)/ Decrease in inventories	10.54	390.84
- (Increase)/ Decrease in other financial assets (Current)	(346.25)	(14.08)
- (Increase)/ Decrease in other financial assets (Non - Current)	(97.28)	53.90
- (Increase)/ Decrease in other Current Assets	(428.29)	(39.74)
- (Increase)/ Decrease in Other non-current Assets	28.08	(136.18)
- Increase/(Decrease) in trade payables	705.54	749.03
- Increase/(Decrease) in Provisions (Current)	149.81	131.41
- Increase/(Decrease) in Provisions (Non - Current)	146.49	58.04
- Increase / (Decrease) in Other current liabilities (Current)	442.59	(117.77)
- Increase / (Decrease) in Other financial liabilities (Current)	683.76	(1,123.92)
Cash generated from operations	15,946.65	12,445.45
Income tax refund / (paid)	(1,384.98)	(1,560.00)
Net cash generated from operating activities	14,561.67	10,885.44
Cash flow from investing activity		
Purchase of Property, Plant & Equipment / CWIP	(9,315.14)	(7,255.30)
Proceeds from sale of Property, Plant & Equipment	264.29	32.42
Maturity / (investments) of / in fixed deposits having original maturity of more than 3 months *	(30,702.90)	(1,866.02)
Loans and Advances given	(29.79)	(114.49)
Interest received	1,245.11	389.89
Net cash (used in) investing activities	(38,538.43)	(8,813.50)
Cash flow from financing activity		
Proceeds from non-current borrowings	2,080.21	4,532.53
Repayment of non-current borrowings	(3,590.06)	(3,329.81)
Proceeds from issuance of shares to non controlling interests	-	178.50
Proceeds from issuance of Equity Share Capital (ESOP)	17.42	17.42
Proceeds from issuance of CCD	33,000.00	-
CCD Transaction Cost	(910.81)	-
Payment of lease liabilities - Principal amount	(564.38)	(388.24)
Payment of lease liabilities - Interest amount	(401.86)	(520.89)
Dividend paid	(597.55)	(611.37)
Interest paid	(2,358.25)	(2,776.06)
Net cash generated from financing activities	26,674.72	(2,897.92)
Net increase in cash & cash equivalents	2,697.96	(825.98)
Cash & cash equivalents as the beginning of the year	1,460.88	2,286.86
Cash & cash equivalents as the end of the year	4,158.84	1,460.88
Components of cash and cash equivalents		
Cash on hand	131.63	102.82
Balances with Banks:		
On current accounts	1,472.21	861.06
Fixed Deposit in banks having original maturity of 3 months or less	2,555.00	497.00
Total Cash and Cash Equivalents	4,158.84	1,460.88

(Note : * This includes investment in fixed deposits of funds received from issuance of CCD amounting to Rs 32205.91 Lacs)



Outsourcing

May 12, 2025

<p>The Secretary, National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051</p> <p>NSE Code: ARTEMISMED</p>	<p>The Secretary, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001</p> <p>Scrip Code: 542919</p>
---	---

Sub: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, in respect of Audit Reports with unmodified opinion for the Financial Year ended March 31, 2025

Dear Sir/Ma'am,


Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016, it is hereby declared that the Statutory Auditors of the Company, M/s. T R Chadha & Co. LLP, Chartered Accountants (Firm Registration No. 006711N/N500028), have issued the Audit Reports with unmodified opinion on the Audited Financial Results (Standalone & Consolidated) of the Company for the financial year ended March 31, 2025.

Submitted for your information and records.

Thanking you.

Yours Faithfully,

For Artemis Medicare Services Limited


Dr. Devlina Chakravarty
Managing Director



Artemis Medicare Services Ltd.

Corporate Office: Sector 51, Gurugram - 122001, Haryana, India
Ph.: +91-124-4511 111 | **Emergency & Trauma: +91-124-4588 888** | Fax: +91-124-4588 899

Registered Office: Plot No. 14, Sector 20, Dwarka, New Delhi - 110075 | CIN: L85110DL2004PLC126414 |
GST: 06AAFCA0130M1Z1 (HR), 07AAFCA0130M1ZZ (DEL) | TAN: DELA16048E | PAN: AAFCA0130M |
Email: info@artemishospitals.com | Web: www.artemishospitals.com

ARTEMIS VENTURES

ARTEMIS
Multi Speciality Hospital

Luxury Mother &
Child Centre
Daffodil
ARTEMIS

ARTEMIS
Cardiac Care

Home Care
Services
SOLACE

Annexure-A**Information as per Regulation 30 and Schedule III of SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024****1. Information about change in Director - Mr. Sunam Sarkar**

S. No.	Particulars	Details
1.	Reason for change	Appointment of Mr. Sunam Sarkar (DIN: 00058859) as an Additional Director in the category of Non-Executive, Non-Independent Director.
2.	Date of appointment & term of appointment	Date of Appointment: Effective from May 12, 2025. Appointed as an Additional Director (Non-Executive, Non-Independent) with effect from May 12, 2025, to hold office upto the date of ensuing Annual General Meeting ("AGM"), and also recommended to be appointed as a Non-Executive Director, liable to retire by rotation, to the Shareholders for their approval at the ensuing AGM.
3.	Brief profile	Mr. Sunam Sarkar holds a Bachelor of Commerce (Honours) degree from St. Xavier's College, Calcutta University, a Diploma in International Management from INSEAD, France, and a Masters in Management from Lancaster University, UK. He began his career as a management trainee at Gelelec Limited. Subsequently, he joined Modi Xerox where he rose to become one of the youngest executives to head a business unit as General Manager. He has over 35 years of experience in the field of sales, marketing, business operations, finance and corporate strategy.
4.	Disclosure of relationships between directors	There is no relationship between Mr. Sunam Sarkar and any other Director of the Company.

2. Information about change in Director - Dr. Nirmal Kumar Ganguly

S. No.	Particulars	Details
1.	Reason for change	Resignation of Dr. Nirmal Kumar Ganguly (DIN: 02316154) as a Non-Executive, Non-Independent Director of the Company with effect from the close of business hours on May 12, 2025 due to personal reasons.
2.	Date of cessation	From the close of business hours on May 12, 2025.
3.	Brief profile (in case of appointment)	Not Applicable
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable



3. Information about change in Director - Ms. Deepa Gopalan Wadhwa

S. No.	Particulars	Details
1.	Reason for change	Ms. Deepa Gopalan Wadhwa (DIN: 07862942) will cease to be a Director of the Company upon the completion of her term as an Independent Director on May 21, 2025.
2.	Date of cessation	May 21, 2025.
3.	Brief profile (in case of appointment)	Not Applicable
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

4. Information about change in senior management - Mr. Pradeep Kumar Saha

S. No.	Particulars	Details
1.	Reason for change	Designated as a member of Senior Management.
2.	Date of appointment & term of appointment	Designated as Senior Management w.e.f. May 12, 2025.
3.	Brief profile (in case of appointment)	Mr. Pradeep Kumar Saha holds a Bachelor of Science (B.Sc) degree from Sambalpur University, Odisha, a Diploma in Computer Management from the Indian Institute of Computer Management, Ahmedabad and Post Graduate Diplomas in Business Management from the Indian Institute of Modern Management, Kolkata and in Computer Science from Data Matics Corporation, Kolkata. He has an overall experience of 40 years and has built an extensive career in the fields of Information Technology, Information Security and Healthcare IT Infrastructure Management.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.



5. Information about change in Secretarial Auditor - M/s. DMK Associates, Practicing Company Secretaries

S. No.	Particulars	Details
1.	Reason for change	Appointment of M/s. DMK Associates, Practicing Company Secretaries, as Secretarial Auditor of the Company to undertake the Secretarial Audit for a period of 5 (five) consecutive years, from FY 2025-26 to FY 2029-30, subject to the approval of the Shareholders of the Company at the ensuing Annual General Meeting ("AGM"), in compliance with the amended Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2.	Date of appointment & term of appointment	<p>Date of appointment: May 12, 2025, subject to the approval of Shareholders.</p> <p>Term of Appointment: To undertake the Secretarial Audit for a period of 5 (five) consecutive years, from FY 2025-26 to FY 2029-30, subject to the approval of the Shareholders of the Company at the ensuing AGM.</p>
3.	Brief profile (in case of appointment)	<p>M/s. DMK Associates, a peer reviewed firm of Practicing Company Secretaries (Peer Review No. 779/2020 & Firm Registration No. P2006DE003100), established and registered with the Institute of Company Secretaries of India in the year 2005 is one of the most reputed firms amongst professionals, several Companies including Listed Companies, multinationals and is best known for its client retention, high integrity, dedication, sincerity, quality of service and professionalism. The firm has been engaged in secretarial audits of various prominent companies and their expertise has earned the trust of industry leaders across sectors like FMCG, Manufacturing, Real estate, Power and Energy, Aggregators, Public utilities and so on.</p> <p>The firm's client centric approach, with experienced professionals and proficient solutions to complex problems prides itself on superior client retention, integrity, dedication, and professionalism making them a trusted partner in navigating the complexities of corporate law.</p>
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable



Date: 5/5/2025

To,
The Board of Directors
Artemis Medicare Services Limited ("the Company")
Plot No.14, Sector-20, Dwarka
South West Delhi-110075

Sub: Resignation from the position of Non-Executive Director of the Company


Dear Board Members,

I, Dr. Nirmal Kumar Ganguly, hereby tender my resignation from the position of Non-Executive, Non-Independent Director of the Company, and consequently from the membership of the Board Committees, with effect from close of the business hours of May 12, 2025. This resignation is due to personal reasons, and there is no other material reason than stated herein.

I would like to convey my gratitude and deep appreciation for the support I received from the Chairman, Managing Director and other Directors on the Board, as well as from the senior management team during my long association with the Company.

I wish the Company all the very best in its future endeavors.

Thanking you.


(Dr. Nirmal Kumar Ganguly)
DIN: 02316154